Quantum BioPharma Wins Legal Battle Against Former CEO, Secures Substantial Cost Award

Quantum BioPharma Ltd. has prevailed in a protracted legal dispute with its former CEO, Dr. Raza Bokhari, after the Court of Appeal for Ontario fully dismissed a reconsideration motion challenging his termination. The court's decision validates the biopharmaceutical company's initial termination of Bokhari for cause in 2021.

The legal proceedings have resulted in significant financial implications for Bokhari. An initial arbitration ruling found against his claim of wrongful dismissal, leading to a cost award of approximately C$2.81 million plus interest. Subsequent court-awarded costs have escalated the total amount due to over C$3 million.

To enforce the judgment, Quantum BioPharma has initiated collection proceedings in the United States. The U.S. District Court for the Eastern District of Pennsylvania has entered a judgment in the company's favor. Despite these developments, Bokhari's appeal remains ongoing, currently stayed and backed by a supersedeas bond exceeding $2.8 million.

The legal victory represents more than a financial triumph for Quantum BioPharma. It demonstrates the company's commitment to corporate governance and its willingness to robustly defend its interests through legal channels. Such actions can signal to investors and stakeholders a strong, principled management approach that prioritizes accountability.

This resolution allows Quantum BioPharma to maintain focus on its core mission of developing innovative treatments for neurodegenerative, metabolic, and alcohol misuse disorders. The company continues to advance its research, including the development of Lucid-MS, a promising compound targeting multiple sclerosis, and maintains strategic investments through its subsidiary, FSD Strategic Investments Inc.